- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04238767
Dolutegravir in Real Life in Lesotho (DO-REAL)
Observational Assessment of the Nation-wide Roll-out of Dolutegravir in Lesotho
DO-REAL is an observational cohort study assessing the large-scale roll-out of the antiretroviral drug dolutegravir (DTG) in Lesotho.
DTG has been shown to have low side-effects and superior treatment outcomes for people living with HIV-1 when compared to other antiretroviral drugs currently in use in low-income countries. The use of DTG in first-line antiretroviral therapy (ART) regimens was recommended by the World Health Organisation in 2018 and adopted by the Ministry of Health in Lesotho in 2019. While DTG-based ART regimens have led to promising health outcomes in high-income and clinical trial settings, certain concerns remain regarding the risk of ART-experienced patients transitioning to a DTG-based ART regimen being placed on a functional monotherapy (increasing the otherwise low risk of viral resistance to DTG) as well as side-effects including psychological symptoms and weight gain.
Thus, the DO-REAL study intends to address these concerns and provide data on health outcomes of HIV patients on DTG in a "real-life" high-prevalence setting.
Study Overview
Detailed Description
SUMMARY: DO-REAL is an observational cohort study assessing the large-scale roll-out of the antiretroviral drug dolutegravir (DTG) in Lesotho.
BACKGROUND: DTG is a second-generation integrase strand transfer inhibitor with low side-effects and superior treatment outcomes for people living with HIV-1 when compared to other antiretroviral drugs currently in use in low-income countries. Though some cases have been described, HIV-1 resistance to DTG is rare in clinical settings when DTG is used as part of a combination therapy. The use of DTG in first-line antiretroviral therapy (ART) regimens was recommended by the World Health Organisation in 2018 and was adopted by the Ministry of Health in Lesotho in 2019. DTG now forms part of the recommended first-line therapy for many ART-naïve patients in Lesotho. In addition, many patients on a non-DTG-based first-line ART regimen will be transitioned to a DTG-based regimen.
OBJECTIVES: Despite the positive health outcomes observed in patients receiving DTG-based ART in high-income countries and in clinical trial settings, there is little data on virologic outcomes of patients on DTG during large-scale implementation in low- and lower middle-income countries. Concerns remain regarding the risk that some patients transitioning to a DTG-based regimen will be placed on a functional monotherapy. Furthermore, there are concerns as to psychological side-effects and observed weight gain. This observational study aims to assess the virologic outcomes (viral suppression rates as well as potential drug resistance) as well as side-effects of people living with HIV-1 and transitioning to a DTG-based ART regimen in Lesotho.
DO-REAL has two major objectives:
- To assess virologic outcomes after the programmatic shift to DTG-based regimens.
- To assess psychological and somatic wellbeing in patients before and after the programmatic shift to DTG-based regimens.
METHODS: DO-REAL is a cohort study enrolling people living with HIV who are initiating or are eligible (according to national guidelines and the local implementation thereof) to initiate a DTG-based antiretroviral therapy (ART) regimen. The study will take place at three hospitals in two districts (Butha-Buthe, Mokhotlong) in Lesotho, and aims to enrol over 2000 participants. Viral loads will be measured on the day of initiating a DTG-based regimen (or on the day this was offered), as well as four, 12 and 24 months thereafter. In a post-hoc analysis, samples will be tested for drug resistance in samples where the viral load permits (approx. ≥100 c/mL). A subset of participants will complete screenings for depression, general health, and HIV-related symptoms.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Butha-Buthe, Lesotho
- Butha-Buthe Government Hospital
-
Butha-Buthe, Lesotho
- Seboche Mission Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- HIV-1-positive
- Initiating or eligible to initiate (offered to initiate) a DTG-based ART regimen
- Informed written consent (and assent, if applicable) provided
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HIV-1-positive individuals
HIV-1-positive individuals eligible to receive a DTG-based ART regimen at enrolment.
|
Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Virologic outcomes after programmatic transition to DTG-containing regimens
Time Frame: 4 months after initiation of a DTG-containing regimen
|
Viral load
|
4 months after initiation of a DTG-containing regimen
|
Quality of life screening score (change from baseline)
Time Frame: Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
|
12-Item Short Form Health Survey (SF-12; 12-item index in which questions are scored and weighted into 2 subscales, physical health and mental health; scores can range from 0-100 with higher scores indicating higher physical or mental health)
|
Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
|
Depression screening score (change from baseline)
Time Frame: Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
|
Patient Health Questionnaire-9 (PHQ-9; 9-item index with each item scored 0-3, providing a 0-27 severity score with a higher score indicating higher severity)
|
Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
|
HIV symptom screening score (change from baseline)
Time Frame: Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
|
Modified HIV Symptom Index (21-item index with each item scored 0-4, providing a 0-84 severity score with a higher score indicating higher severity)
|
Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Virologic status at programmatic transition to DTG-containing regimens
Time Frame: On day of initiation of a DTG-containing regimen
|
Viral load (post-hoc analysis)
|
On day of initiation of a DTG-containing regimen
|
Viral drug resistance at programmatic transition to DTG-containing regimens
Time Frame: On day of initiation of a DTG-containing ART regimen
|
HIV-1 drug resistance (assessed by Sanger sequencing) in the case of an unsuppressed viral load (post-hoc analysis)
|
On day of initiation of a DTG-containing ART regimen
|
Weight (change from baseline)
Time Frame: On day of initiation of a DTG-containing ART regimen and 4, 12 and 24 months thereafter
|
Change from time of enrolment; median and interquartile range; in kg
|
On day of initiation of a DTG-containing ART regimen and 4, 12 and 24 months thereafter
|
Reasons for discontinuation of a DTG-containing regimen
Time Frame: Up to 24 months after enrolment
|
Reasons for discontinuing a DTG-containing regimen as noted in medical records, where applicable
|
Up to 24 months after enrolment
|
Long-term virologic outcomes after programmatic transition to DTG-containing regimens
Time Frame: 12 and 24 months after initiation of a DTG-containing regimen
|
Viral load
|
12 and 24 months after initiation of a DTG-containing regimen
|
Viral drug resistance after programmatic transition to DTG-containing regimens
Time Frame: 4, 12 and 24 months after initiation of a DTG-containing regimen
|
HIV-1 drug resistance (assessed by Sanger sequencing) in the case of an unsuppressed viral load
|
4, 12 and 24 months after initiation of a DTG-containing regimen
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Josephine Muhairwe, MD, MPH, SolidarMed Lesotho
- Principal Investigator: Jennifer A Brown, MSc, MAS D&C, Swiss Tropical & Public Health Institute
- Study Chair: Niklaus D Labhardt, MD, MIH, Swiss Tropical & Public Health Institute
- Study Director: Thomas Klimkait, PhD, University of Basel
Publications and helpful links
General Publications
- Brown JA, Nsakala BL, Mokhele K, Rakuoane I, Muhairwe J, Urda L, Amstutz A, Tschumi N, Klimkait T, Labhardt ND. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study). HIV Med. 2022 Mar;23(3):287-293. doi: 10.1111/hiv.13189. Epub 2021 Oct 10.
- Brown JA, Nsakala BL, Mokhele K, Rakuoane I, Muhairwe J, Glass TR, Amstutz A, Tschumi N, Belus JM, Klimkait T, Labhardt ND. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho. HIV Med. 2023 Feb;24(2):153-162. doi: 10.1111/hiv.13352. Epub 2022 Jun 22.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P001-19-1.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Pseudonymized dataset for the published manuscripts "Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study)" and "Dolutegravir in Real Life: self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho" are publicly available on Zenodo:
https://zenodo.org/record/5948369 https://zenodo.org/record/6654462
Study Data/Documents
-
Individual Participant Data Set
Information identifier: 10.5281/zenodo.6654462Information comments:
Dataset relating to:
Brown JA, Nsakala BL, Mokhele K, et al. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho. HIV Med. Published online June 22, 2022. doi:10.1111/hiv.13352
-
Individual Participant Data Set
Information comments:
Dataset relating to:
Brown JA, Nsakala BL, Mokhele K, et al. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study). HIV Med. 2022;23(3):287-293. doi:10.1111/hiv.13189
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1-infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on Dolutegravir
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV InfectionsUnited States
-
ViiV HealthcareCompleted
-
University of KwaZuluCentre for the AIDS Programme of Research in South AfricaRecruitingTuberculosis | HivSouth Africa
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHIVUnited States, Brazil, Puerto Rico, South Africa, Thailand
-
Fundación HuéspedViiV HealthcareCompletedHIV-1 InfectionArgentina
-
Thomas BenfieldRecruitingCardiovascular Diseases | HIV Infections | Hiv | Weight Change, Body | HIV Lipodystrophy | HIV CardiomyopathyDenmark
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States